Human 4-1BBR/TNFRSF9 (Recombinant)

<strong>Human 4-1BBR/TNFRSF9</strong>_x000D_ <strong>Catalog number:</strong> B2010338_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 ug_x000D_ <strong>pH:</strong> 7.4 upon reconstitution_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure Human 4-1BBR/TNFRSF9 expressed in E. coli. This protein acts as an inducible T cell molecule belonging to the TNF receptor superfamily, involved in the expansion of antigen-specific T cells as well as in the inhibition of activation-induced death of CD8+ T cells._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> rHu4-1BBR/TNFRSF9; CD137_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: So T, Ishii N. The TNF-TNFR Family of Co-signal Molecules. Adv Exp Med Biol._x000D_ 2019;1189:53-84._x000D_ _x000D_ 2: Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing_x000D_ R, Gao R, Zhang L, Dong M, Hu X, Ren X, Kirchhoff D, Roider HG, Yan T, Zhang Z._x000D_ Global characterization of T cells in non-small-cell lung cancer by single-cell_x000D_ sequencing. Nat Med. 2018 Jul;24(7):978-985._x000D_ _x000D_ 3: Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, Sen D, Nager_x000D_ AR, Oakdale NS, Brown C, Wang F, Yang Y, Lindquist K, Yeung YA, Salek-Ardakani_x000D_ S, Chaparro-Riggers J. Structure of the 4-1BB/4-1BBL complex and distinct_x000D_ binding and functional properties of utomilumab and urelumab. Nat Commun. 2018_x000D_ Nov 8;9(1):4679._x000D_ _x000D_ 4: Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP,_x000D_ Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas_x000D_ RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by_x000D_ tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581-90._x000D_ _x000D_ 5: Chu DT, Bac ND, Nguyen KH, Tien NLB, Thanh VV, Nga VT, Ngoc VTN, Anh Dao DT,_x000D_ Hoan LN, Hung NP, Trung Thu NT, Pham VH, Vu LN, Pham TAV, Thimiri Govinda Raj_x000D_ DB. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int J Mol_x000D_ Sci. 2019 Apr 12;20(8):1822._x000D_ _x000D_ 6: Etxeberria I, Glez-Vaz J, Teijeira Á, Melero I. New emerging targets in_x000D_ cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open. 2020_x000D_ Jul;4(Suppl 3):e000733._x000D_ _x000D_ 7: Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K,_x000D_ Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone_x000D_ CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G. Antitumor_x000D_ Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via_x000D_ Chimeric Antigen Receptor T Cells. Cancer Cell. 2019 Feb 11;35(2):221-237.e8._x000D_ _x000D_ 8: Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of_x000D_ co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity._x000D_ J Autoimmun. 2018 Dec;95:77-99._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31105267/">9: Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X. Optimization of 4-1BB_x000D_ antibody for cancer immunotherapy by balancing agonistic strength with FcγR_x000D_ affinity. Nat Commun. 2019 May 20;10(1):2141. </a>_x000D_ _x000D_ <strong>Products Related to Human 4-1BBR/TNFRSF9 </strong> <a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>